Assessment of Parkinson disease: What do we need to show neuroprotection?

  • Ybot-Gorrin I
  • Vivancos-Matellano F
  • Chacón-Peña J
 et al. 
  • 7

    Readers

    Mendeley users who have this article in their library.
  • 4

    Citations

    Citations of this article.

Abstract

To date, no pharmacological agent has convincingly demonstrated the ability to slow the progression of Parkinson disease (PD). The development of treatments that slow down the progressive degeneration of the nigrostriatal dopaminergic system (true neuroprotection), which is ultimately responsible for the patients' functional decline, has become one of the basic goals of PD research. In this review, we have attempted to analyze the role of different methods that measure PD severity (basically, clinical scales, timed tests, and neuroimaging techniques) in the evaluation of the "neuroprotection" provided by different types of treatment for the disease, on the basis of clinical evidence.

Author-supplied keywords

  • Parkinson disease
  • clinical evaluation
  • dopaminergic therapy
  • neuroimaging
  • neuroprotection
  • rating scales
  • timed tests

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Isabel Ybot-Gorrin

  • Francisco Vivancos-Matellano

  • José Rafael Chacón-Peña

  • Hortensia Alonso-Navarro

  • Félix Javier Jiménez-Jiménez

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free